Selected Podcast

What Are Radiopharmaceuticals and How Are They Changing Cancer Treatment?

In this informative episode, Dr. Rod Ellis takes us inside the world of radiopharmaceuticals and describes how liquid radiation can target cancer cells directly. He discusses the role of these therapies in fighting specific types of cancer and breaks down how this treatment option is reshaping the patient experience, especially for those with limited treatment options. Tune in to discover how science, precision, and hope are coming together to transform the fight against cancer.


What Are Radiopharmaceuticals and How Are They Changing Cancer Treatment?
Featured Speaker:
Rod Ellis, MD

Rodney J. Ellis, MD, FACRO, is a Professor in the Departments of Radiation Oncology at University of South
Florida and is the departments Director for Clinical Research. Dr. Ellis previously served as Chair for Penn State University as well as the Vice Chairman for Clinical Affairs and Medical Director as well as Director Genitourinary Oncology, Brachytherapy and Advanced Image Guided
Radiotherapy in the Department of Radiation Oncology at University Hospitals Seidman Cancer Center. Dr. Ellis
received his MD from Northeastern Ohio Universities College of Medicine. He was a radiation oncology resident
and Chief Resident at Ohio State University Arthur James Cancer Hospital and a preliminary medicine intern at
Akron General Medical Center.

Dr. Ellis has published over 100 peer-reviewed articles in journals such as the Journal of Gastroenterology, the
International Journal of Radiation Oncology, Biology, Physics, and Brachytherapy to name a few. He has been
invited to present his research nationally and internationally. His primary research interest is in molecular imaging
for prostate cancer and radiation therapy planning for advanced image guided radiation applications. He is an
Internation PI for NRG GU-005. He is also the local PI for The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer at Tampa General Hospital.

Dr. Ellis remains active in cooperative group studies in addition to his investigator-initiated trials in GU Oncology.
He remains in the NRG GU Steering Committee, and serves on the NCI
Renal Task Force as a Co-Chair.